Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments from global product sales.
Otsuka Pharmaceutical obtains worldwide rights for the development and commercialization of the CAN10 program.
LUND, SE / / July 15, 2025 / Cantargia AB (publ) (Cantargia) (Nasdaq Stockholm:CANTA) today announced that it has entered into an agreement with Japanese healthcare company Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) pursuant to which Otsuka Pharmaceutical will acquire all Cantargia's assets related to its early-clinical stage CAN10 program. Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment and is eligible to up to additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales. The transaction, subject to customary closing conditions and regulatory approval, is expected to close in the third quarter of 2025.
Otsuka Pharmaceutical will be fully responsible for the development and commercialization of CAN10 globally. Otsuka Pharmaceutical will direct and perform all future development, apply for regulatory approvals and exclusively carry out manufacturing and sales of the product worldwide. In addition to the CAN10 antibody, Otsuka Pharmaceutical acquires 3G5 [1] as a backup antibody and will also have exclusive first rights of negotiation regarding the next-generation IL-1RAP antibodies to be developed by Cantargia for a period of 2 years.
CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines of the IL-1-super family: IL-1, IL-33 and IL-36. CAN10 is currently being evaluated in an ongoing phase 1 clinical trial.
"This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune inflammatory disorders." said Cantargia's Interim Chief Executive Officer Damian Marron. "We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases."
Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., Ltd., commented, "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our U.S. subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our U.S. subsidiary Jnana Therapeutics. This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients."
[1] 3G5 is a pre-clinical IL1RAP targeting antibody which is similar to CAN10.
For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: damian.marron@cantargia.com
This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-15 08:45 CEST.
About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com .
About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling of the cytokines of the IL1-super family via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing.
About Otsuka PharmaceuticalOtsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide.
For further information, please visit www.otsuka.co.jp/en/
AttachmentsCantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical
SOURCE: Cantargia
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SAP is acquiring SmartRecruiters
SAP announced Friday that it has reached an agreement to acquire recruiting software company SmartRecruiters. In a press release, the European software giant said that SmartRecruiters 'powerful, user-friendly interfaces and seamless workflows' will complement SAP's existing HR tools. Muhammad Alam, the SAP executive board member who leads product and engineering, said in a statement that with this acquisition, 'Customers will be able to manage the entire candidate lifecycle — from sourcing and interviewing to onboarding and beyond — all in a single system to streamline the experience for recruiters, hiring managers and, in particular, candidates.' The terms of the acquisition were not disclosed. The deal is expected to close in the fourth quarter of this year. SmartRecruiters' last announced round of funding was a $110 million Series E in 2021, which valued the company at $1.5 billion.
Yahoo
an hour ago
- Yahoo
GigaCloud Technology (GCT) Surges 59% In Last Quarter
GigaCloud Technology recently announced the leasing of a new fulfillment center in Germany and the approval of a class action settlement, which adds to its operational and legal framework enhancements. These developments might have added weight to the company's share price increase of 59% over the last quarter, even as the broader market experienced turbulence, tumbling by 18% recently amid trade uncertainties and weaker job data. Participation in key events like the Las Vegas Market and being added to multiple indices could have further supported the GigaCloud's value, aligning the company slightly counter to the recent market downturn. We've discovered 1 possible red flag for GigaCloud Technology that you should be aware of before investing here. We've found 22 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent developments at GigaCloud Technology, including the leasing of a new fulfillment center in Germany and the class action settlement approval, could bolster their European market share and operational stability. These enhancements have the potential to improve both revenue and earnings forecasts, aligning with their rebranding efforts and integration strategies. With analysts projecting a revenue increase to US$1.3 billion by 2028, the new center may significantly contribute to this growth path. Over the last year, GigaCloud's total shareholder return, including share price and dividends, decreased by 17.96%. Despite this decline, the company's shares have increased by 59% over the most recent quarter, a stark contrast to the broader market's 18% decline amid economic uncertainties. This performance indicates a potential reversal of sentiment, although it lags compared to the 17.5% return of the overall U.S. market and the US Retail Distributors industry's 14.9% drop within the same timeframe. The current share price of US$20.97 shows a significant discount to the consensus price target of US$29.5, indicating analysts' expectations of higher future value. The recent strategic moves highlight potential for growth in earnings and market positioning, aiding in closing this valuation gap. As the company navigates macroeconomic challenges and competitive pressures, the fulfillment center might be a pivotal factor in achieving the forecasted outcomes, although reaching earnings of US$82.1 million by 2028 with a PE ratio of 13.4x remains a challenge that reflects analysts' mixed opinions on GigaCloud's future trajectory. Upon reviewing our latest valuation report, GigaCloud Technology's share price might be too pessimistic. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GCT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Zazzaroni Reveals ‘Atalanta Shareholders Blocking Lookman Sale' After Bombshell Transfer Request
Corriere dello Sport editor Ivan Zazzaroni believes it is the owners and shareholders of Atalanta who have been blocking the sale of Ademola Lookman to Inter Milan. Zazzaroni took to Instagram after the latest development of Lookman publicly handing in a transfer request. Earlier today, Atalanta forward Ademola Lookman made a public message asking for a transfer. The Nigerian's previous gesture had not exactly been subtle. He scrubbed all traces of his current employers from his social media accounts. However, now Lookman has spelled it out in plain English. View this post on Instagram The 27-year-old went as far as to accuse Atalanta of 'poor treatment' and of 'breaking a promise' due to their not selling him in a timely manner. Therefore, this could embolden Inter to push even harder for Lookman's signature. Zazzaroni: 'Atalanta Shareholders Blocking Ademola Lookman Sale' BOLOGNA, ITALY – SEPTEMBER 28: Ademola Lookman of Atalanta BC looks on during the Serie A match between Bologna and Atalanta at Stadio Renato Dall'Ara on September 28, 2024 in Bologna, Italy. (Photo by) Corriere dello Sport editor Ivan Zazzaroni, who first broke the news of Inter's interest in Lookman, gave his thoughts on the state of the transfer saga. 'In the end, Marotta was right to interpret the no to the €45 million offer as an affirmation that the player was considered unsellable,' Zazzaroni writes. This, in particular 'after the sale of Retegui.' 'Considering that now the player feels that he must publicly force their hand.' Furthermore, Zazzaroni rights that 'the real obstacle now is Stephen Pagliuca.' The US businessman is part-owner of Atalanta. 'Who along with the other shareholders owns 55% of Atalanta.' Zazzaroni then adds that 'Inter are in no rush.'
